PE20010404A1 - Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres - Google Patents

Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres

Info

Publication number
PE20010404A1
PE20010404A1 PE2000000580A PE0005802000A PE20010404A1 PE 20010404 A1 PE20010404 A1 PE 20010404A1 PE 2000000580 A PE2000000580 A PE 2000000580A PE 0005802000 A PE0005802000 A PE 0005802000A PE 20010404 A1 PE20010404 A1 PE 20010404A1
Authority
PE
Peru
Prior art keywords
testosterone
level
estradiol
serum
androgenic steroids
Prior art date
Application number
PE2000000580A
Other languages
English (en)
Inventor
Theresa Rosario-Jansen
Norman A Mazer
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Publication of PE20010404A1 publication Critical patent/PE20010404A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL USO DE ESTEROIDES ANDROGENICOS TAL COMO TESTOSTERONA, METILTESTOSTERONA, ANDROESTENEDIONA, ADRENOSTERONA, DESHIDROEPIANDROSTERONA, OXIMETOLONA, FLUOXUMESTERONA, METANDROSTENOLONA, DIHIDROTESTOSTERONA, DANAZOL, OXIMETOLONA, ANDROSTERONA, NANDROLONA, ESTANOSOLOL, ETILESTRENOL, OXANDROLONA, BOLASTERONA, MESTEROLONA, PROPIONATO DE TESTOSTERONA, CIPIONATO DE TESTOSTERONA, FENILACETATO DE TESTOSTERONA, ENTRE OTROS. EL ESTEROIDE ANDROGENICO SE PUEDE PRESENTAR EN FORMA TOPICA O PARENTERAL SUFICIENTE PARA LOGRAR UN EFECTO TERAPEUTICO EQUIVALENTE i)A UN NIVEL DE SUERO LIBRE DE TESTOSTERONA DE 0,5 pg/ml A 30 pg/ml; ii)A UN NIVEL DE TESTOSTERONA BIODISPONIBLE EN EL SUERO DESDE 1 ng/ml A 70 ng/ml; iii)A UN NIVEL TOTAL DE TESTOSTERONA EN EL SUERO DE 15 ng/dl A 1000ng/dl; UTILIZANDOSE 50 mcg/DIA. TAMBIEN SE PUEDE USAR CON a)UN SUPLEMENTO DE ESTROGENO ADMINISTRADO ORALMENTE TAL COMO 17 O-ESTRADIOL, 17 ß-ESTRADIOL, ESTROGENO ESTERIFICADO, ESTRADIOL MICRONIZADO, SULFATO DE ESTROGENO, ESTRADIOL ETINIL, ESTRONA, FITOESTROGENO, UTILIZANDOSE 0,2 mg/DIA A 3 mg/DIA; b)PROGESTINA QUE PROPORCIONA SEGURIDAD ENDOMETRICA O COMO ANTICONCEPTIVO. EL USO DE ESTEROIDES ANDROGENICOS PUEDE SER UTIL CUANDO EL NIVEL DE GLOBULINA DE ENLACE CON LA HORMONA SEXUAL SE ENCUENTRA ELEVADO COMO DE 84 nmol/L
PE2000000580A 1999-06-11 2000-06-09 Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres PE20010404A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13932399P 1999-06-11 1999-06-11
US13885199P 1999-06-11 1999-06-11
US13885499P 1999-06-11 1999-06-11

Publications (1)

Publication Number Publication Date
PE20010404A1 true PE20010404A1 (es) 2001-04-09

Family

ID=27385240

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000580A PE20010404A1 (es) 1999-06-11 2000-06-09 Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres

Country Status (25)

Country Link
US (3) US6583129B1 (es)
EP (1) EP1189619A4 (es)
JP (2) JP5184727B2 (es)
KR (2) KR20020011437A (es)
CN (1) CN1220491C (es)
AR (1) AR024566A1 (es)
AU (1) AU775145B2 (es)
BR (1) BR0011740A (es)
CA (1) CA2376797C (es)
CO (1) CO5180583A1 (es)
CZ (1) CZ299198B6 (es)
HK (1) HK1048269B (es)
HU (1) HUP0301813A2 (es)
IL (1) IL147010A0 (es)
MX (1) MXPA01012769A (es)
MY (1) MY126960A (es)
NO (1) NO20016046L (es)
NZ (1) NZ516502A (es)
PE (1) PE20010404A1 (es)
PL (1) PL352250A1 (es)
SA (1) SA00210404B1 (es)
SK (1) SK18212001A3 (es)
TR (1) TR200200406T2 (es)
TW (1) TWI281398B (es)
WO (1) WO2000076522A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2234060A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6624200B2 (en) * 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
CO5180583A1 (es) * 1999-06-11 2002-07-30 Watson Pharmaceuticals Inc Administracion de esteroides androgenicos no orales a las mujeres
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020151530A1 (en) * 2000-12-22 2002-10-17 Leonard Thomas W. Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
DE60228583D1 (de) * 2001-07-09 2008-10-09 Repros Therapeutics Inc Verfahren und materialien für die behandlung des testosteron-mangels bei männern
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
WO2003030894A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
EP1441707A1 (en) * 2001-11-09 2004-08-04 Pharmacia AB Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
US20140212508A1 (en) * 2001-12-20 2014-07-31 John Wayne Kennedy Copper/zinc superoxide dismutase (sod) formulation for the treatment of traumas including amyotropic lateral sclerosis
US20030216366A1 (en) * 2002-04-03 2003-11-20 Leonard Thomas W. Step-down estrogen therapy
EP1350541A1 (de) * 2002-04-04 2003-10-08 Jenapharm GmbH & Co. KG Verwendung von einem Dehydroepiandrosteron und einem Estradiol Derivat zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung klimakterischer Beschwerden in der Postmenopause
WO2003105825A1 (en) * 2002-06-14 2003-12-24 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat vaginal dryness
IL152575A (en) 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
IL152573A (en) 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
EP2292239A3 (en) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
IL157535A0 (en) * 2003-08-21 2004-03-28 Topimed Ltd Preparations for the prevention of skin atrophy
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
DE60303854T2 (de) 2003-11-11 2006-08-10 Mattern, Udo Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen
EP1776098A1 (en) * 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
CN102357248A (zh) 2004-10-20 2012-02-22 恩多研究公司 单独的性甾体前体或与选择性***受体调节剂联合用于防治绝经后女性的***疾病和病症
US20150005360A1 (en) 2004-10-25 2015-01-01 Nse Products, Inc. Phytoestrogen compositions and associated methods
CN101115477A (zh) * 2005-02-04 2008-01-30 雷普罗斯治疗公司 用反式氯米芬治疗***的方法和物质
EP1858522A4 (en) * 2005-03-02 2008-07-16 Pharmaceutical Inc Nascent PHARMACEUTICALLY ACCEPTABLE CARRIER FOR OPHTHALMIC COMPOSITIONS
JP5785680B2 (ja) * 2005-03-22 2015-09-30 リプロス セラピューティクス インコーポレイテッド トランス−クロミフェン用の投与レジメン
WO2007012815A1 (en) * 2005-07-27 2007-02-01 Ingenia Technology Limited Authenticity verification
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
US20080015170A1 (en) * 2005-12-01 2008-01-17 The Procter & Gamble Company Method of treating menopausal women transdermally with testosterone
BRPI0711525A2 (pt) 2006-06-02 2011-11-01 Pear Tree Women S Health Care composição farmacêutica e método para tratar sintomas de vaginite atrófica
US20080045486A1 (en) * 2006-08-17 2008-02-21 Tang-Liu Diane D S Ocular administration of testosterone
PL2068825T3 (pl) 2006-10-04 2011-06-30 M & P Patent Ag Układ dostarczania o kontrolowanym uwalnianiu do donosowego podawania związków neuroprzekaźnikowych
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CA2702710C (en) 2007-10-16 2013-05-07 Repros Therapeutics, Inc. Trans-clomiphene for metabolic syndrome
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
US20090285893A1 (en) * 2008-05-19 2009-11-19 The Procter & Gamble Company Treatment of heart failure in women
US9572817B2 (en) * 2008-07-04 2017-02-21 The Heart Research Institute Ltd. Use of androgens for vascular regeneration and endothelial repair
US9795617B2 (en) 2009-06-18 2017-10-24 Baucom Institute for Longevity and Life Enhancement, Inc. Hormone delivery system and method
US8658628B2 (en) * 2009-06-18 2014-02-25 Karan Y. Baucom Hormone delivery system and method
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130231317A1 (en) * 2011-07-19 2013-09-05 Michael S. Riepl Dhea bioadhesive controlled release gel
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9713621B2 (en) * 2012-01-19 2017-07-25 Edward Lichten Treatment of endometriosis
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2889770A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
BR112015013106A2 (pt) * 2012-12-05 2017-07-11 Ge Nutrients Inc uso de extrato de feno-grego para melhorar a libido feminina
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
WO2014149998A1 (en) * 2013-03-15 2014-09-25 Lin, Qing Systemic administration of androgen in treating dry eye syndrome
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3737374B1 (en) 2018-01-10 2024-04-03 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
BE1027858B1 (fr) * 2019-12-13 2021-07-14 Georges Debled Composition pharmaceutique pour la contraception chez la femme
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550107A (en) * 1895-11-19 Thirds to henry zervas and julius wegert
US4210664A (en) * 1979-03-02 1980-07-01 Merrell Toraude Et Compagnie Use of α,α'-dithiobis(β-arylacrylic acid) derivatives to enhance zinc serum and tissue concentrations
FR2573307B1 (fr) * 1984-11-22 1988-06-10 Virbac Ctre Rech Biolog Implants anabolisants a liberation prolongee
US4983395A (en) 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
ES2077675T3 (es) 1989-03-10 1995-12-01 Endorecherche Inc Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
ATE275957T1 (de) * 1993-01-19 2004-10-15 Endorech Inc Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
NZ536787A (en) 1998-06-11 2006-03-31 Endorech Inc Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta diol
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CO5180583A1 (es) * 1999-06-11 2002-07-30 Watson Pharmaceuticals Inc Administracion de esteroides androgenicos no orales a las mujeres

Also Published As

Publication number Publication date
US20070190120A1 (en) 2007-08-16
CA2376797A1 (en) 2000-12-21
AU775145B2 (en) 2004-07-22
BR0011740A (pt) 2002-05-14
SK18212001A3 (sk) 2002-04-04
AR024566A1 (es) 2002-10-16
TWI281398B (en) 2007-05-21
HK1048269A1 (en) 2003-03-28
JP2003505345A (ja) 2003-02-12
CN1367698A (zh) 2002-09-04
MXPA01012769A (es) 2003-06-24
KR20070063609A (ko) 2007-06-19
NO20016046L (no) 2002-02-06
HUP0301813A2 (hu) 2003-09-29
NZ516502A (en) 2004-03-26
IL147010A0 (en) 2002-08-14
EP1189619A1 (en) 2002-03-27
CA2376797C (en) 2011-03-22
SA00210404B1 (ar) 2006-08-21
WO2000076522A1 (en) 2000-12-21
JP2013049682A (ja) 2013-03-14
MY126960A (en) 2006-11-30
PL352250A1 (en) 2003-08-11
AU5475800A (en) 2001-01-02
CN1220491C (zh) 2005-09-28
US6583129B1 (en) 2003-06-24
US8551516B2 (en) 2013-10-08
EP1189619A4 (en) 2004-06-09
KR20020011437A (ko) 2002-02-08
HK1048269B (zh) 2006-01-13
CO5180583A1 (es) 2002-07-30
CZ20014499A3 (cs) 2002-05-15
CZ299198B6 (cs) 2008-05-14
US20030153540A1 (en) 2003-08-14
TR200200406T2 (tr) 2002-06-21
US7186706B2 (en) 2007-03-06
JP5184727B2 (ja) 2013-04-17
NO20016046D0 (no) 2001-12-11

Similar Documents

Publication Publication Date Title
PE20010404A1 (es) Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres
Øverlie et al. Androgens and estrogens in relation to hot flushes during the menopausal transition
Adams et al. Estrogenic effects of physiological concentrations of 5-androstene-3β, 17β-diol and its metabolism in MCF7 human breast cancer cells
Chowdhury et al. Effect of 5α reduced androgens on sex accessory organs. Initiation and maintenance of spermatogenesis in the rat
UA48973C2 (uk) Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції
CA2467237A1 (en) Method of preventing or treating benign gynaecological disorders
CA2431645A1 (en) Methods of treating hormonal deficiencies in women undergoing estrogen replacement therapy
EP0680327A1 (en) Therapeutic uses and delivery systems of dehydroepiandrosterone
Gompel et al. Tibolone actions on normal and breast cancer cells
Di Prisco et al. Identification and biosynthesis of steroids in the marine mollusc Aplysia depilans
Goebelsmann et al. In vitro steroid metabolic studies in testicular 17β-reduction deficiency
Deitel et al. Sex hormonal changes accompanying loss of massive excess weight
MXPA02004084A (es) Nueva composicion hormonal y su utilizacion.
NZ333862A (en) Triphasic oral contraceptive method and kit comprising a combination of progestin and estrogen
Nolte et al. Increase of serum estradiol in cirrhotic men treated by transjugular intrahepatic portosystemic stent shunt
Schaison et al. Male pseudohermaphroditism due to testicular 17-ketosteroid reductase deficiency
Vihko et al. Regulation of steroidogenesis in testis
Stanczyk et al. Androstenedione is an important precursor of dihydrotestosterone in the genital skin of women and is metabolized via 5α-androstanedione
KAMADA Study on 17-Ketosteroids in Umbillical Cord Blood
Sridharan et al. Induction of ovulation by pregn-5-ene-3, 20-dione and progesterone in immature rats treated with PMSG and phenobarbital
RU2220976C1 (ru) ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ [H3]-3-ГИДРОКСИЭСТРА-1,3,5(10)-ТРИЕН-17-ОН ИЛИ 17β-ЭСТРА-1,3,5(10)-ТРИЕН-3,17-ДИОЛ
Mendoza et al. Comparative effects of short term treatment with norethisterone and sex steroids on gonadotropin secretion in rat pituitary cell cultures
Park et al. A Case of 17a-Hydroxylase Deficiency in 17-Year-Old Girl.
PASQUALINI et al. the journal of steroid biochemistry
Vermeulen Leydig Cell Secretion in (Pre) Pubertal Boys and in Delayed Puberty

Legal Events

Date Code Title Description
FC Refusal